Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?

被引：348

作者：

Ottenhoff, Tom H. M. ^{[1
]}

Kaufmann, Stefan H. E. ^{[2
]}

机构：

[1] Leiden Univ, Med Ctr, Dept Infect Dis, Leiden, Netherlands

[2] Max Planck Inst Infect Biol, Deptartment Immunol, Berlin, Germany

来源：

PLOS PATHOGENS | 2012年 / 8卷 / 05期

基金：

比尔及梅琳达.盖茨基金会;

关键词：

T-CELL RESPONSES; HEPARIN-BINDING HEMAGGLUTININ; CALMETTE-GUERIN VACCINATION; DRUG-RESISTANT TUBERCULOSIS; HOST-PATHOGEN INTERACTIONS; MYCOBACTERIUM-BOVIS BCG; IMMUNE-RESPONSE; LATENT INFECTION; EXTRAPULMONARY DISSEMINATION; POLYFUNCTIONAL CD4(+);

D O I：

10.1371/journal.ppat.1002607

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

In this review we discuss recent progress in the development, testing, and clinical evaluation of new vaccines against tuberculosis (TB). Over the last 20 years, tremendous progress has been made in TB vaccine research and development: from a pipeline virtually empty of new TB candidate vaccines in the early 1990s, to an era in which a dozen novel TB vaccine candidates have been and are being evaluated in human clinical trials. In addition, innovative approaches are being pursued to further improve existing vaccines, as well as discover new ones. Thus, there is good reason for optimism in the field of TB vaccines that it will be possible to develop better vaccines than BCG, which is still the only vaccine available against TB.

引用

页数：12

共 50 条

[1] Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?
Guapillo, Carolina
Hernandez-Pando, Rogelio
Alberto Flores-Valdez, Mario
[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (05) : 1193 - 1195
[2] Diagnosing Malnutrition: Where Are We and Where Do We Need to Go?
Compher, Charlene
Mehta, Nilesh M.
[J]. JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS, 2016, 116 (05) : 779 - 784
[3] Where are we in conservation genetics and where do we need to go?
Richard Frankham
[J]. Conservation Genetics, 2010, 11 : 661 - 663
[4] Glaucoma screening: where are we and where do we need to go?
Tan, Nicholas Y. Q.
Friedman, David S.
Stalmans, Ingeborg
Ahmed, Iqbal Ike K.
Sng, Chelvin C. A.
[J]. CURRENT OPINION IN OPHTHALMOLOGY, 2020, 31 (02) : 91 - 100
[5] Where are we in conservation genetics and where do we need to go?
Frankham, Richard
[J]. CONSERVATION GENETICS, 2010, 11 (02) : 661 - 663
[6] Arthritis and employment research: Where are we? Where do we need to go?
Lacaille, D
[J]. JOURNAL OF RHEUMATOLOGY, 2005, 32 : 42 - 45
[7] RNA virus vectors: Where are we and where do we need to go?
Palese, P
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (22) : 12750 - 12752
[8] The oropharyngeal delivery of interferons: Where are we and where do we need to go?
Bocci, V
[J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1999, 19 (08): : 859 - 861
[9] A half century later: Where are we? Where do we need to go?
Barraga, NC
[J]. JOURNAL OF VISUAL IMPAIRMENT & BLINDNESS, 2004, 98 (10) : 581 - 583
[10] Syndesmotic Injuries: Where Are We Now? Where Do We Need To Go?
Mediouni, Mohamed
Schlatterer, Daniel R.
Gardner, Michael
[J]. JOURNAL OF FOOT & ANKLE SURGERY, 2017, 56 (05): : 1129 - 1129

← 1 2 3 4 5 →